Share via:
The funding round was also co-led by Shastra VC and Kotak Alternate Asset Managers’ Life Sciences Fund I
The company plans to use the fresh funds to boost its IP portfolio and support the clinical development of its lead candidate AVA-NP-695
Founded in 2020, Avammune Therapeutics is a biopharmaceutical startup working on discovery of small molecule medicines
Healthtech startup Avammune Therapeutics has raised $12 Mn (INR 100 Cr) as a part of its Series A funding round…
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
The funding round was also co-led by Shastra VC and Kotak Alternate Asset Managers’ Life Sciences Fund I
The company plans to use the fresh funds to boost its IP portfolio and support the clinical development of its lead candidate AVA-NP-695
Founded in 2020, Avammune Therapeutics is a biopharmaceutical startup working on discovery of small molecule medicines
Healthtech startup Avammune Therapeutics has raised $12 Mn (INR 100 Cr) as a part of its Series A funding round…
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi
